OTC Markets Group (OTCM) Q2 2024 earnings summary

Executive summary

• Q2 2024 gross revenues reached $27.6 million, up 1% year-over-year, while net income declined 3% to $6.7 million and operating margin fell to 30.4% from 31.4%.

• OTC Link led business line growth with a 12% increase, while market data licensing rose 1% and corporate services revenue declined 3%.

• Strategic priorities include expanding global trading, enhancing data-driven markets, launching new products like OTC Overnight, and increasing regulatory compliance.

• Operating expenses increased 1% year-over-year, totaling $17.1 million, with compensation costs comprising 64% of OpEx.

• A quarterly dividend of $0.18 per share was declared for Q2 and Q3 2024, reflecting ongoing shareholder return commitment.

Financial highlights

• Q2 2024 gross revenues were $27.6 million, up 1% year-over-year; net income was $6.7 million, down 3%.

• OTC Link revenues increased 12%, representing 20% of total gross revenues; market data licensing rose 1% and contributed 39%.

• Blue Sky data product revenues increased 35%; internal system licenses and other data services rose 10%.

• Corporate services revenues, 41% of gross revenues, decreased 3% year-over-year.

• Adjusted EBITDA was $10.3 million (down 1%), adjusted diluted EPS was $0.85 (down 1%), and diluted GAAP EPS was $0.56 (down 2%).

• Cash from operations was $6.2 million, up from $4.7 million; free cash flow was $5.5 million, up from $4.4 million.

Outlook and guidance

• Focus remains on global trading expansion, new product launches (e.g., OTC Overnight), and enhancing data and compliance offerings.

• Ongoing investment in compliance, technology, and risk management to support scalable, long-term growth.

• Management views growth as non-linear, emphasizing continuous improvement and adaptation.

• Forward-looking statements are subject to risks and uncertainties as outlined in the annual report.